Istradefylline (Nourianz) for Parkinson ' s Disease

Date: February 10, 2020 Issue #:  1591Summary:  The FDA has approved istradefylline (Nourianz— Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson ' s disease (PD) who experience " off " episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research